Dunen Medical Secures Nearly RMB 100 Million in New Financing to Accelerate Advancement of Pharmaceutical Services

VCBeat has learned that, recently,Hangzhou Dunen Medical Laboratory Co., Ltd.(hereinafter referred to as “Dun'en Medicine”)Announces Completion of New Round of Financing, Chen Zhijun, Founder of Dunen Medical; Tu Jixian, Deputy General Manager of CICC Capital Operations Co., Ltd.; Shao Xiangrong, Deputy Secretary of the Party Committee at Zhejiang Tsinghua Yangtze Delta Region Institute; and Professor Chen Shuqing from the College of Pharmaceutical Sciences, Zhejiang University, among other leaders, jointly attended the financing signing ceremony.

This round of financing amounted to nearly RMB 100 million, led by CICC Capital, with participation from other well-known domestic funds.Upon the completion of this round of strategic financing, Dunen Medicine will be fully committed to building a pharmaceutical care industry ecosystem. This initiative encompasses the construction and operation of a clinical precision medication platform; the research and development of products related to pharmacogenetic testing and therapeutic drug monitoring; the establishment of a precision medication database; the development of big data-driven medication guidance software and AI pharmacists; as well as the provision of clinical services for innovative drug R&D.

Chen Zhijun, Founder of Dun En MedicineIt was stated: “Through our arduous efforts in the early stages, Dunen Medicine has now grown into a vibrant and innovative biopharmaceutical enterprise with significant growth potential. We are deeply grateful for the recognition from the capital markets. This financing round will propel Dunen Medicine’s rapid development. Seizing this opportunity, we remain grounded, pragmatic, and truth-seeking. We are confident in scaling up our operations and establishing ourselves as the leading enterprise in pharmaceutical care services.”

Shao Xiangrong, Deputy Secretary of the Party Committee, Zhejiang Yangtze Delta Region Institute of Tsinghua UniversityIt indicates that Dunen Medical has a young and dynamic team, and we highly recognize its strategic layout in the pharmaceutical care industry.It is a biopharmaceutical enterprise that the research institute has prioritized for incubation and development.The Zhejiang Yangtze Delta Region Institute of Tsinghua University will continue to provide Dunen Medical with services such as talent acquisition, talent development, and technological innovation, with the hope that Dunen will become a unicorn enterprise in this niche sector.

Prof. Shuqing Chen, College of Pharmaceutical Sciences, Zhejiang UniversityIt was stated that irrational drug use is one of the major challenges facing medicine, leading to suboptimal clinical therapeutic outcomes and severe adverse reactions that may even result in significant patient mortality. It is hoped that Dunen Medicine will adopt a patient-centered approach, comprehensively enhance the quality of pharmaceutical care services, and play a significant role in promoting the high-quality development of precision pharmacy in the future.

Founded in 2017, Dunen Medical is a leading high-tech enterprise in China dedicated to providing clinical precision medication guidance services. As the operational entity for the “Precision Medication Research Center” under the Hangzhou Branch of the Yangtze Delta Region Institute of Tsinghua University, Zhejiang, the company focuses primarily on the high-potential market of precision medication services. Dunen Medical boasts a robust R&D team, with over one-third of its members holding master’s degrees or higher. The company remains committed to delivering superior and reliable precision medication solutions to medical experts and patients worldwide, striving tirelessly to advance global health.

CICC Capital is a wholly-owned private equity investment management subsidiary of China International Capital Corporation Limited (“CICC”). As CICC’s platform for private equity fund business, it centrally manages the company’s domestic and overseas private equity fund activities. The types of funds under its management include RMB corporate equity investment funds, funds of funds, real estate funds, infrastructure funds, and USD corporate equity investment funds. By the end of 2021, CICC Capital had cumulative assets under management exceeding RMB 400 billion, supported by a professional investment management team of more than 400 members, making it a leading comprehensive alternative asset investment management platform in China with international influence.

The Yangtze Delta Region Institute of Tsinghua University in Zhejiang is a pioneer and leader in Zhejiang Province’s implementation of the strategy to “introduce prestigious universities and research institutes and jointly build innovation platforms.” Since its establishment in 2003, the Institute has been based in Zhejiang and oriented toward the Yangtze River Delta region. By adopting a self-financing, market-oriented operational model, it has explored an effective mode of provincial-university cooperation. It has introduced and cultivated more than 1,000 high-level overseas talents for Zhejiang, making it one of the earliest launched and largest platforms in China for recruiting overseas talent and intelligence. In 2019, the Institute was included as the sole innovation platform in the national strategic plan, the Outline of the Integrated Development Plan for the Yangtze River Delta Region. In 2020, it was recognized as one of the “Top Ten Industry-University-Research Integration Organizations” at the national level, being the only new-type R&D institution from Zhejiang Province to receive this honor.